risk management

Treatment Reduces, Exterminates Hospitalizations in Adults With Moderate to Severe AD

Individuals with atopic dermatitis (AD) who were treated with dupilumab were found to experience less frequent, and shorter hospitalizations, according to new research.1

Researchers set out to compare hospitalization rates in adults with moderate to severe AD who use dupilumab for treatment vs a control treatment. They analyzed data from 7 randomized, controlled trials of dupilumab in various doses (300 mg every 2 weeks and/or weekly; with or without topical corticosteroids).

Patients who received treatment (every 2 weeks and weekly, n = 1841) had lower cases of all-cause hospitalizations (5.8, 2.7, and 3.8 events, respectively, vs 9.0 events per 100 patient-years [PY]; all P<.05 [49%, 71%, and 62% risk reduction, respectively]), and AD-related hospitalizations (2.0, 0.4, 1.0 events vs 4.1 events per 100 PY; P < .05 weekly and dupilumab combined [91% and 79% risk reduction, respectively]) than control group patients (n = 1091).

Those who received treatment also experienced shorter AD-related hospitalization (10.9, 7.3, and 8.6 days vs 38.9 days per 100 PY).

“Among adults with moderate-to-severe AD, treatment with dupilumab versus control was associated with significant reductions in all-cause and AD-related hospitalization rates, and shorter duration of AD-related hospitalization,” researchers concluded.

 

—Cristalia Turck

 

References:

  1. Silverberg JI, Rubini NPM, Pires MC, et al. Dupilumab treatment reduces hospitalizations in adults with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol Pract. Published online ahead of print January 12, 2022. doi:10.1016/j.jaip.2021.11.034